Open: 51.61 Close: 52.39 Change: 0.78

Today's Summary

Novo Nordisk shares jumped on Tuesday following news that the Food and Drug Administration (FDA) had formally approved its application to sell a pill form of Wegovy in the United States. This new version of the drug will give the pharmaceutical giant a crucial tool to push back against the pressure it has faced from competition. Court in Beijing backs validity of Novo Nordisks compound patent for semaglutide. Main ingredient in obesity therapy Wegovy and diabetes treatments Ozempic and Rybelsus. Ruling is particularly important this year.